The latest update from Medtronic’s (NYSE:MDT) ADVANCE registry of patients treated with the CoreValve transcatheter aortic valve implantation evaluated the technology from a cost perspective, with researchers reporting that CoreValve is worth the money for patients with severe aortic stenosis.
Cardiovascular
Welcome to MassDevice's Cardiovascular Hub, your resource for the latest news in cardiac implants, structural heart, heart valves, stents and more. Stay informed about the innovations and business news shaping the cardiovascular device industry.
🫀 Narrow your focus with these categories:
Cardiac Implants | Structural Heart | Pulsed-Field Ablation
Here are top cardiology features from MassDevice and its sister publications (and scroll down to read the latest cardiology device news from MassDevice):
+ LVADs save lives: So why aren’t more available?
+ How Medtronic uses nitinol to improve the structure and effectiveness of heart devices
+ How Abbott designed the world’s first dual-chamber leadless pacemaker system
+ J&J used RWE for expanded indications — and you can, too
+ 7 cardiology startups you need to know
Latest Cardiology News
Abbott touts CE Mark for “world’s longest” coronary DES
Stentys enrolls 1st patient in U.S. stent trial
Stentys SA (EPA:STNT) hoping a new U.S. clinical trial will help it win pre-market approval for a self-apposing coronary stent.
The Princeton, N.J.- and Paris-based medical device company said it enrolled the 1st patient in its Apposition V trial, under an investigational device exemption from the U.S. watchdog agency.
Claret Medical’s filter thwarts debris headed for the brain in TAVI patients, study shows
Claret Medical’s Montage Dual Filter system is poised to become a staple of transcatheter aortic valve implantation procedures if the company has anything to say about it.
In an original manuscript published by researcher Dr. Nicolas Van Mieghem he concluded that the Montage device captured "embolic debris" traveling to the brain in 75% of patients undergoing TAVI.
Biosensors International wins CE Mark for latest line of drug-eluting stents
Biosensors International (PINK:BSNRY) said it won a green light from European regulators for its BioMatrix NeoFlex drug-eluting stent, the latest in its DES line.
Tryton Medical launches side-branch stent in Europe
UPDATED May 17, 2013 with comment from Tryton CEO Shawn McCarthy.
Tryton Medical said it got the green light in Europe for its side-branch short coronary stent to treat bifurcation lesions in large vessels.
The new stent is 15mm, 3mm shorter in the main branch zone than the standard Tryton side-branch stent, the Durham, N.C.-based medical device company said.
Direct Flow Medical wins FDA approval for U.S. trial of new heart valve
The FDA granted Direct Flow Medical an investigational device exemption for its transcatheter aortic valve implant, with the medical device company announcing enrollment in its Salus feasibility trial.
St. Jude Medical wins EU green light for Ilumien Optis
St. Jude Medical (NYSE:STJ) today announced CE Mark approval of its Ilumien Optis PCI optimization system, designed to help physicians assess and treat patients with coronary artery disease.
Boston Scientific hits new 52-week high on WallFlex stent trial launch
Boston Scientific (NYSE:BSX) shares hit a new 52-week high today after the medical device company announced the launch of a clinical trial of its WallFlex biliary stent.
Valve-in-valve implantation for failed heart valves shows good short-term results
The short-term results of minimally invasive transcatheter valve-in-valve implantation to treat failed biological heart valve protheses are "excellent," but patients must be closely monitored due to some notable cases of suboptimal systolic-valve performance, according to early data from a multi-center trial.
New share buyback goads Edwards Lifesciences up 7%
Edwards Lifesciences (NYSE:EW) said it plans to buy back another $750 million worth of its own stock during the 2nd quarter, with CEO Michael Mussallem buying another $5 million worth on his own.